Renin-angiotensin system inhibitor discontinuation in COVID-19 did not modify systemic ACE2 in a randomized controlled trial

Despite the similar clinical outcomes after renin-angiotensin system (RAS) inhibitor (RASi) continuation or withdrawal in COVID-19, the effects on angiotensin-converting enzyme 2 (ACE2) and RAS metabolites remain unclear. In a substudy of the randomized controlled Austrian Corona Virus Adaptive Clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rathkolb, Vincent, Traugott, Marianna T., Heinzel, Andreas, Poglitsch, Marko, Aberle, Judith, Eskandary, Farsad, Abrahamowicz, Agnes, Mueller, Martin, Knollmueller, Petra, Shoumariyeh, Tarik, Stuflesser, Jasmin, Seeber, Ivan, Gibas, Georg, Mayfurth, Hannah, Tinhof, Viktoria, Schmoelz, Lukas, Zeitlinger, Markus, Schoergenhofer, Christian, Jilma, Bernd, Genser, Bernd, Hoepler, Wolfgang, Omid, Sara, Karolyi, Mario, Wenisch, Christoph, Oberbauer, Rainer, Zoufaly, Alexander, Hecking, Manfred, Reindl-Schwaighofer, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585392/
https://www.ncbi.nlm.nih.gov/pubmed/37867935
http://dx.doi.org/10.1016/j.isci.2023.108146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585392/
https://www.ncbi.nlm.nih.gov/pubmed/37867935
http://dx.doi.org/10.1016/j.isci.2023.108146

Ejemplares similares